Multiple myeloma has gone from a disease with a 3-year average survival in the 1990s to one where many patients live a decade or more. CAR-T cell therapy and bispecific antibodies are now changing the landscape again, producing deep remissions in patients whose disease has stopped responding to multiple lines of treatment.
What's actually going on in research
Trials are testing CAR-T therapy and bispecific antibodies earlier in treatment, four-drug combinations for newly diagnosed patients, and new targets beyond BCMA. Researchers are also studying minimal residual disease testing to guide how long to treat, treatments for high-risk genetic features, and approaches for smoldering myeloma to prevent progression.
CAR-T cell therapy
CAR-T therapies targeting BCMA are producing deep, lasting remissions in heavily pretreated myeloma. Trials are now moving CAR-T to earlier lines, including newly diagnosed patients.
Bispecific antibodies
Off-the-shelf bispecifics that engage the immune system against myeloma cells are giving an option to patients who cannot wait for CAR-T manufacturing. Several are now approved.
Earlier intervention
Studies are testing whether treating high-risk smoldering myeloma — before symptoms — can prevent progression and extend life. Earlier results are encouraging.
What to know before you search
Eligibility often depends on prior treatments, response to past therapy, genetic features of the myeloma, kidney function, and overall health.
What types of trials are currently open
- Treatment trials — Testing new drugs or combinations in people with myeloma to see if they extend remission or work in resistant disease.
- CAR-T and cell therapy trials — Studies of engineered immune cells designed to attack myeloma, often for relapsed disease.
- Maintenance trials — Testing treatments given during remission to keep the myeloma from coming back.
- Stem cell transplant trials — Testing newer transplant approaches and how they fit alongside CAR-T and other new therapies.
- Prevention trials — Testing treatments in people with smoldering myeloma or precursor conditions to prevent progression.
Recently added Multiple Myeloma trials
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of immunotherapy in patients with multiple myeloma, while remaining safe and well-tolerated. Patients will be randomly assigned to one of four intervention groups or a control group. The intervention groups will either follow a ketogenic diet (less than 10% of calories from carbohydrates) or receive oral supplementation with deltaG® Ketone Monoester Performance \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate; CAS 1208313-97-6; TdeltaS Global, Inc., Oxford, UK\], administered orally three times daily at either a low dose (13.5 g per serving, 40.5 g/day) or a high dose (25 g per serving, 75 g/day), in accordance with the FDA GRAS-approved dosing range. The control group will receive standard nutritional care. The study includes two parts: Part A enrolls patients receiving bispecific antibody treatment, and Part B enrolls patients receiving CAR-T cell therapy. Both dosing levels are applied in each part.
Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma
The goal of this clinical trial is to evaluate the effect of a long-term, individualized, hybrid adapted physical activity program on the quality of life of patients with multiple myeloma. The main question it aims to answer are : Does this logn term, individualized and hybrid adapted physical activity program improve quality of life in multiple myeloma patient ? What are the effects of this program on effort tolerance, pain, muscular mass, osteolytic lesions, tolerance to treatment, response to treatment? If there is a comparison group: Researchers will compare \[arm information\] to see if \[insert effects\]. Participants will be randomised in 2 groups. * control group: patients will receive only advices about physical activities benefit * interventional group: This group will be offered a program of adapted physical activities mixing sessions at home (remote) and sessions at the hospital (in person).
Find Multiple Myeloma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.